metformin has been researched along with Acute Symptom Flare in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Mestier, L | 1 |
| Védie, AL | 1 |
| Faron, M | 1 |
| Cros, J | 1 |
| Rebours, V | 1 |
| Hentic, O | 1 |
| Do Cao, C | 1 |
| Bardet, P | 1 |
| Lévy, P | 1 |
| Sauvanet, A | 1 |
| Ruszniewski, P | 1 |
| Hammel, P | 1 |
| Sun, F | 1 |
| Geng, S | 1 |
| Wang, H | 2 |
| Liu, Z | 1 |
| Wang, X | 1 |
| Li, T | 1 |
| Wan, W | 1 |
| Lu, L | 1 |
| Teng, X | 1 |
| Morel, L | 1 |
| Ye, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus[NCT02741960] | Phase 4 | 180 participants (Actual) | Interventional | 2016-05-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for metformin and Acute Symptom Flare
| Article | Year |
|---|---|
Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials.
Topics: Adult; Double-Blind Method; Female; Humans; Lupus Erythematosus, Systemic; Male; Metformin; Middle A | 2020 |
1 other study available for metformin and Acute Symptom Flare
| Article | Year |
|---|---|
The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metfor | 2020 |